Combined use of high-sensitivity cardiac troponin T and N-terminal pro-B type natriuretic peptide improves measurements of performance over established mortality risk factors in chronic heart failure
- PMID: 22607860
- DOI: 10.1016/j.ahj.2012.03.004
Combined use of high-sensitivity cardiac troponin T and N-terminal pro-B type natriuretic peptide improves measurements of performance over established mortality risk factors in chronic heart failure
Abstract
Background: Heart failure still maintains a high mortality. Biomarkers reflecting different pathophysiological pathways are under evaluation to better stratify the mortality risk. The objective was to assess high-sensitivity cardiac troponin T (hs-cTnT) in combination with N-terminal pro-B type natriuretic peptide (NT-proBNP) for risk stratification in a real-life cohort of ambulatory heart failure patients.
Methods: We analyzed 876 consecutive patients (median age 70.3 years, median left ventricular ejection fraction 34%) treated at a heart failure unit. A combination of biomarkers reflecting myocyte injury (hs-cTnT) and myocardial stretch (NT-proBNP) was used in addition to an assessment based on established mortality risk factors (age, sex, left ventricular ejection fraction, New York Heart Association functional class, diabetes, estimated glomerular filtration rate, ischemic etiology, sodium, hemoglobin, β-blocker treatment, and angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment).
Results: During a median follow-up of 41.4 months, 311 patients died. In the multivariable Cox proportional hazards model, hs-cTnT and NT-proBNP were independent prognosticators (P = .003 each). The combined elevation of both biomarkers above cut-off values significantly increased the risk of death (HR 7.42 [95% CI, 5.23-10.54], P < .001). When hs-cTnT and NT-proBNP were individually included in a model with established mortality risk factors, measurements of performance significantly improved. Results obtained for hs-cTnT compared with NT-proBNP were superior according to comprehensive discrimination, calibration, and reclassification analysis (net reclassification indices of 7.7% and 1.5%, respectively).
Conclusions: hs-cTnT provides significant prognostic information in a real-life cohort of patients with chronic heart failure. Simultaneous addition of hs-cTnT and NT-proBNP into a model that includes established risk factors improves mortality risk stratification.
Copyright © 2012 Mosby, Inc. All rights reserved.
Similar articles
-
Combined use of the novel biomarkers high-sensitivity troponin T and ST2 for heart failure risk stratification vs conventional assessment.Mayo Clin Proc. 2013 Mar;88(3):234-43. doi: 10.1016/j.mayocp.2012.09.016. Epub 2013 Feb 4. Mayo Clin Proc. 2013. PMID: 23384388 Clinical Trial.
-
Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure.Eur J Heart Fail. 2011 Jul;13(7):718-25. doi: 10.1093/eurjhf/hfr047. Epub 2011 May 6. Eur J Heart Fail. 2011. PMID: 21551163
-
Importance of early combined N-terminal pro-brain natriuretic peptide and cardiac troponin T measurements for long-term risk stratification of patients with decompensated heart failure.J Heart Lung Transplant. 2006 Oct;25(10):1230-40. doi: 10.1016/j.healun.2006.08.004. J Heart Lung Transplant. 2006. PMID: 17045936
-
Changes of natriuretic peptides predict hospital admissions in patients with chronic heart failure: a meta-analysis.JACC Heart Fail. 2014 Apr;2(2):148-58. doi: 10.1016/j.jchf.2013.11.007. JACC Heart Fail. 2014. PMID: 24720923 Review.
-
Prognostic Value of High-Sensitivity Troponin T in Chronic Heart Failure: An Individual Patient Data Meta-Analysis.Circulation. 2018 Jan 16;137(3):286-297. doi: 10.1161/CIRCULATIONAHA.117.031560. Circulation. 2018. PMID: 29335288
Cited by
-
Prognostic value of high-sensitivity cardiac troponin I in patients with non-ischaemic heart failure: insights from China.ESC Heart Fail. 2022 Oct;9(5):3345-3357. doi: 10.1002/ehf2.14065. Epub 2022 Jul 13. ESC Heart Fail. 2022. PMID: 35831235 Free PMC article.
-
Utility of high-sensitivity cardiac troponin T in patients receiving anthracycline chemotherapy.Vasc Health Risk Manag. 2015 Nov 24;11:591-4. doi: 10.2147/VHRM.S89842. eCollection 2015. Vasc Health Risk Manag. 2015. PMID: 26648730 Free PMC article.
-
Circulating Biomarkers for Monitoring Chemotherapy-Induced Cardiotoxicity in Children.Pharmaceutics. 2023 Nov 30;15(12):2712. doi: 10.3390/pharmaceutics15122712. Pharmaceutics. 2023. PMID: 38140053 Free PMC article. Review.
-
Cardiac Myosin Activators in Systolic Heart Failure: More Friend than Foe?Curr Cardiol Rep. 2016 Oct;18(10):100. doi: 10.1007/s11886-016-0778-x. Curr Cardiol Rep. 2016. PMID: 27568794 Review.
-
Structure and function of the Nppa-Nppb cluster locus during heart development and disease.Cell Mol Life Sci. 2018 Apr;75(8):1435-1444. doi: 10.1007/s00018-017-2737-0. Epub 2018 Jan 4. Cell Mol Life Sci. 2018. PMID: 29302701 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials